Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, today announced that its lead candidate for idiopathic pulmonary fibrosis (IPF), TXR-1002, demonstrated significant efficacy in new preclinical research. TXR-1002 represents a completely new novel mechanism of action for the potential treatment of IPF. Data was presented at the 6th Annual Antifibrotic Drug Development Summit on November 10 in Boston.

Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, announced that the company has successfully filed a total of six provisional patents with the United States Patent and Trademark Office (USPTO) for lead candidates in its lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) research programs.

TXR-1002 and TXR-1007, demonstrated significant efficacy and excellent tolerability in preclinical studies.

Aria Pharmaceuticals will transition from drug discovery partnerships to advancing its own novel therapies in an expanding pipeline across 18 different therapeutic programs.

Both TXR-1208 and TXR-1210 demonstrated significant decrease in kidney fibrosis and inflammation compared to TGFbeta mAb, the standard metric for positive efficacy.

In vivo screening supports TRX-611 and TRX-612 as potential treatment candidates just weeks after program initiation.

In validation studies, TRX-311 demonstrated greater activity and selectivity in killing HCC tumor cells than standard of care, sorafenib, and significantly inhibited growth in two HCC patient-derived xenograft (PDX) tumor models. TRX-311 also demonstrated in vivo efficacy comparable to sorafenib with good tolerability.

Howard Rosen is a Veteran Pharmaceutical Leader and has Held Senior Positions at Some of the World's Top Pharmaceutical Companies.

Novel leads were identified in four weeks through twoXAR's proprietary AI platform and then evaluated through in vivo screening.

Dr. Eller is an accomplished pharmaceutical industry executive who brings 30 years of R&D experience. Dr. Pandey is a leader in the pharmaceutical industry bringing 25 years of experience in all stages of drug discovery and development.